Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspension

Cytometry Part A

Volumn 81 A, Issue 9, 2012, Pages 776-784

  Minderman, Hans ^a   Humphrey, Kristen ^a   Arcadi, Jane K ^a   Wierzbicki, Andrzej ^a   Maguire, Orla ^a   Wang, Eunice S ^a   Block, Annemarie W ^a   Sait, Sheila N J ^a   George, Thaddeus C ^b   Wallace, Paul K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Amnis Corporation   (United States)

Author keywords

Acute myeloid leukemia; FISH in suspension; ImageStream; Minimal residual disease

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ALGORITHM; ANEUPLOIDY; ARTICLE; BIOLOGICAL MODEL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMAGE PROCESSING; LIMIT OF DETECTION; MALE; MONONUCLEAR CELL; PATHOLOGY; REPRODUCIBILITY; SINGLE CELL ANALYSIS;

ALGORITHMS; ANEUPLOIDY; FEMALE; FLOW CYTOMETRY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; LIMIT OF DETECTION; MALE; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; SINGLE-CELL ANALYSIS;

EID: 84865423325     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.22101     Document Type: Article

References (29)

1. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115-136.
2. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann IC, Stevens R, Burnett A, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1, 612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood 1998; 92: 2322-2333.
3. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
4. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
5. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-1320.
6. Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, Vardiman JW, Pettenati MJ, Baer MR, Qumsiyeh MB, Koduru PR, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood 2006; 108: 63-73.
7. Mrozek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 2008; 35: 365-377.
8. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.
9. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819.
10. DiNardo CD, Luger SM. Beyond morphology: Minimal residual disease detection in acute myeloid leukemia. Curr Opin Hematol 2012; 19: 82-88.
11. Marcucci G, Mrozek K, Ruppert AS, Archer KJ, Pettenati MJ, Heerema NA, Carroll AJ, Koduru PR, Kolitz JE, Sterling LJ, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: Results from cancer and leukemia group B study 8461. J Clin Oncol 2004; 22: 2410-2418.
12. Bacher U, Kern W, Schoch C, Schnittger S, Hiddemann W, Haferlach T. Evaluation of complete disease remission in acute myeloid leukemia: A prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer 2006; 106: 839-847.
13. Barch MJ, Knutsen T, Spurbeck JL. The AGT Cytogenetics Laboratory Manual. Philadelphia: Lippincott Raven; 1997.
14. Ortyn WE, Perry DJ, Venkatachalam V, Liang L, Hall BE, Frost K, Basiji DA. Extended depth of field imaging for high speed cell analysis. Cytometry A 2007; 71A: 215-231.
15. Ossenkoppele GJ, van de Loosdrecht AA, Schuurhuis GJ. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol 2011; 153: 421-436.
16. Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, Mateos MV, Cibeira MT, Cordon L, Oriol A, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012; 119: 687-691.
17. Baines P, Austin S, Fisher J, Owen-Jones E, Lee-Jones L, Throp D, McKinley M, Hoy T, Mills K, Thompson P, et al. Increased circulating normal and BCR-ABL+Ve progenitor numbers in Philadelphia chromosome-positive acute myeloid leukaemia. Leuk Res 2002; 26: 997-1005.
18. Engel H, Drach J, Keyhani A, Jiang S, Van NT, Kimmel M, Sanchez-Williams G, Goodacre A, Andreeff M. Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells. Leukemia 1999; 13: 568-577.
19. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, Galkin S, Collector MI, Perkins B, Levis MJ, et al. A clinically relevant population of leukemic CD34+CD38- cells in acute myeloid leukemia. Blood 2012; 119: 3571-3577.
20. Varella-Garcia M, Hogan CJ, Odom LF, Murata-Collins JL, Ai H, Chen L, Richkind K, Paskulin G, Andreeff M, Brizard A, et al. Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting. Leukemia 2001; 15: 1408-1414.
21. White DL, Hutchins CJ, Turczynowicz S, Suttle J, Haylock DN, Hughes TP, Juttner CA, To LB. Detection of minimal residual disease in an AML patient with trisomy 8 using interphase fish. Pathology 1997; 29: 289-293.
22. Bayani J, Squire JA. Fluorescence in situ Hybridization (FISH). Curr Protoc Cell Biol 2004; 22:Unit 22 4.
23. Batliwalla FM, Damle RN, Met C, Chiorazzi N, Gregersen PK. Simultaneous flow cytometric analysis of cell surface markers and telomere length: Analysis of human tonsilar B cells. J Immunol Methods 2001; 247: 103-109.
24. Ferguson-Smith MA, Zheng YL, Carter NP. Simultaneous immunophenotyping and FISH on fetal cells from maternal blood. Ann N Y Acad Sci 1994; 731: 73-79.
25. Hessel H, Mittermuller J, Zitzelsberger Hy, Weier HU, Bauchinger M. Combined immunophenotyping and FISH with sex chromosome-specific DNA probes for the detection of chimerism in epidermal Langerhans cells after sex-mismatched bone marrow transplantation. Histochem Cell Biol 1996; 106: 481-485.
26. Korac P, Jones M, Dominis M, Kusek R, Mason DY, Banham AH, Ventura RA. Application of the FICTION technique for the simultaneous detection of immunophenotype and chromosomal abnormalities in routinely fixed, paraffin wax embedded bone marrow trephines. J Clin Pathol 2005; 58: 1336-1338.
27. Zhang Y, Siebert R, Matthiesen P, Harder S, Theile M, Scherneck S, Schlegelberger B. Feasibility of simultaneous fluorescence immunophenotyping and fluorescence in situ hybridization study for the detection of estrogen receptor expression and deletions of the estrogen receptor gene in breast carcinoma cell lines. Virchows Arch 2000; 436: 271-275.
28. Sargent RL, Cook JR, Aguilera NI, Surti U, Abbondanzo SL, Gollin SM, Swerdlow SH. Fluorescence immunophenotypic and interphase cytogenetic characterization of nodal lymphoplasmacytic lymphoma. Am J Surg Pathol 2008; 32: 1643-1653.
29. Martin-Subero JI, Chudoba I, Harder L, Gesk S, Grote W, Novo FJ, Calasanz MJ, Siebert R. Multicolor-FICTION: Expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses. Am J Pathol 2002; 161: 413-420.